According to the data, Indian companies’ total profits are expected to grow 25% in the next fiscal year, which would be the highest in Asia. Photo: Mint

Bengaluru: Earnings for companies in Nifty rose at their best pace in six quarters during July-September, according to Thomson Reuters Eikon data, showcasing how profits are finally looking up after a prolonged spell of sluggish growth.

Net profits for companies in the National Stock Exchange’s Nifty 50 index rose by an average of 11.9% in the September quarter, the biggest gain since a 31% expansion in January-March 2016, data available for 25 companies in the index showed.

That was a median 5.2% above consensus forecasts, the biggest beat since the March 2016 quarter.

According to the data, Indian companies’ total profits are expected to grow 25% in the next fiscal year, which would be the highest in Asia.

Analysts said the results in the quarter were a needed validation for a stock market that has surged this year on bets that earnings would improve. This follows India’s action to remove high-value currency bills late last year that dented the cash-dependant economy, leading to several quarters of sluggish profit growth.

The results also highlighted how Indian companies withstood the unveiling of a national goods and services tax (GST) on 1 July, which sent profits down 3.1% for the Nifty companies in the April-June quarter as they curbed production to prepare for the tax rollout.

“It’s the beginning of better times, as far as India Inc is concerned,” said Deven Choksey, promoter of KR Choksey Group.

“The economy is gaining momentum, this is the beginning of higher earnings for the corporate sector.”

The NSE index has surged nearly 27% this year, setting a record-breaking rally.

Sectors such as consumer goods and auto makers posted strong profit growth, in a welcome indication that demand was improving, analysts said.

But telecom firms posted a drop in profits as the sector continues to be hurt by cutthroat competition from upstart Jio Infocomm, while healthcare stocks were hit by regulatory scrutiny and pricing pressure in the key United States market.